NEW YORK, Dec. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0763017/United-States-In-Vitro-Diagnostics-Market-Outlook-to-2018--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. - 2011 company shares and distribution shares data for each of the seven market categories.- Global corporate-level profiles of key companies operating within the United States In Vitro Diagnosticsmarket. - Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the United States In Vitro Diagnostics competitive landscape.- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.- What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 71.2 List of Figures 132 Introduction 162.1 What is This Report About? 163 In Vitro Diagnostics In United States 173.1 In Vitro Diagnostics, Market Segmentation 173.2 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 183.3 In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2011 203.4 In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 213.5 In Vitro Diagnostics, United States, Company Share (2010-2011) 284 Clinical Chemistry In United States 304.1 Clinical Chemistry, Market Segmentation 304.2 Clinical Chemistry Market, United States, Revenue Mix ($m), 2011 314.3 Clinical Chemistry Market, United States, Segment Contribution (%), 2011 324.4 Clinical Chemistry Overall Revenue, (2004-2018) 334.5 Clinical Chemistry Distribution Share (2010-2011) 454.6 Clinical Chemistry, United States, Company Share (2010-2011) 465 Genetic Testing In United States 475.1 Genetic Testing, Market Segmentation 475.2 Genetic Testing Market, United States, Revenue Mix ($m), 2011 485.3 Genetic Testing Market, United States, Segment Contribution (%), 2011 495.4 Genetic Testing Overall Revenue, (2004-2018) 505.5 Genetic Testing Distribution Share (2010-2011) 545.6 Genetic Testing, United States, Company Share (2010-2011) 556 Haematology In United States 576.1 Haematology Market, Market Segmentation 576.2 Haematology Market, United States, Revenue Mix ($m), 2011 586.3 Haematology Market, United States, Segment Contribution (%), 2011 596.4 Haematology Overall Revenue, (2004-2018) 606.5 Haematology Distribution Share (2010-2011) 846.6 Haematology, United States, Company Share (2010-2011) 857 Histology And Cytology In United States 877.1 Histology and Cytology Market, Market Segmentation 877.2 Histology And Cytology Market, United States, Revenue Mix ($m), 2011 887.3 Histology And Cytology Market, United States, Segment Contribution (%), 2011 897.4 Histology And Cytology Overall Revenue, (2004-2018) 907.5 Histology And Cytology Distribution Share (2010-2011) 947.6 Histology And Cytology, United States, Company Share (2010-2011) 958 Immuno Chemistry In United States 978.1 Infectious Immunology, Market Segmentation 978.2 Immuno Chemistry Market, United States, Revenue Mix ($m), 2011 988.3 Immuno Chemistry Market, United States, Segment Contribution (%), 2011 998.4 Immuno Chemistry Overall Revenue, (2004-2018) 1008.5 Immuno Chemistry Distribution Share (2010-2011) 1288.6 Immuno Chemistry, United States, Company Share (2010-2011) 1299 Infectious Immunology In United States 1319.1 Infectious Immunology Market, United States, Revenue Mix ($m), 2011 1319.2 Infectious Immunology Market, United States, Segment Contribution (%), 2011 1329.3 Infectious Immunology Overall Revenue, (2004-2018) 1339.4 Infectious Immunology Distribution Share (2010-2011) 1419.5 Infectious Immunology, United States, Company Share (2010-2011) 14210 Microbiology Culture In United States 14410.1 Microbiology Culture, Market Segmentation 14410.2 Microbiology Culture Market, United States, Revenue Mix ($m), 2011 14510.3 Microbiology Culture Market, United States, Segment Contribution (%), 2011 14610.4 Microbiology Culture Overall Revenue, (2004-2018) 14710.5 Microbiology Culture Distribution Share (2010-2011) 15510.6 Microbiology Culture, United States, Company Share (2010-2011) 15611 Overview of Key Companies in United States In Vitro Diagnostics Market 15811.1 Siemens Healthcare 15811.2 Abbott Laboratories 15911.3 F. Hoffmann-La Roche Ltd. 16011.4 Beckman Coulter, Inc. 16111.5 Ortho-Clinical Diagnostics Inc. 16211.6 Alere Inc. 16311.7 Danaher Corporation 16411.8 bioMerieux S.A. 16411.9 Becton, Dickinson and Company 16511.10 Bio-Rad Laboratories, Inc. 16511.11 Sysmex Corporation 16611.12 Qiagen N.V. 16611.13 Gen-Probe Incorporated 16711.14 DiaSorin S.p.A 16711.15 Immucor, Inc. 16811.16 Cepheid 16811.17 Thermo Fisher Scientific Inc. 16911.18 Hologic, Inc. 16911.19 PerkinElmer, Inc. 17011.20 Grifols, S.A. 17011.21 Olympus Corporation 17111.22 Horiba, Ltd. 17111.23 Life Technologies Corporation 17211.24 Diagnostica Stago, Inc. 17211.25 ELITech Group 17311.26 OraSure Technologies, Inc. 17312 In Vitro Diagnostics Market Pipeline Products 17412.1 Clinical Chemisty Market Pipeline Products 17412.2 Immuno Chemistry Market Pipeline Products 18112.3 Haematology Market Pipeline Products 19212.4 Infectious Immunology Market Pipeline Products 19412.5 Microbiology Culture Market Pipeline Products 20112.6 Histology And Cytology Market Pipeline Products 20212.7 Genetic Testing Market Pipeline Products 20313 Financial Deals Landscape 20813.1 Acquisition 20813.2 Partnerships 23914 Recent Developments 33014.1 Strategy And Business Planning 33014.2 Research And Development 35314.3 Legal and Regulatory 35914.4 Government and Public Interest 38114.5 Product News 42815 Appendix 52515.1 Definitions of Markets Covered in the Report 52615.2 Research Methodology 53715.3 Secondary Research 53715.4 Primary Research 53815.5 Models 53815.6 Forecasts 53915.7 Expert Panels 53915.8 GlobalData Consulting 53915.9 Contact Us 54015.10 Disclaimer 540

List of Tables

Table 1: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 36Table 2: In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 38Table 3: In Vitro Diagnostics Market, United States, Cross-Category Analysis, 2004-2018 40Table 4: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 42Table 5: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 44Table 6: In Vitro Diagnostics, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 46Table 7: Clinical Chemistry Market, United States, Segment Contribution (%), 2011 49Table 8: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51Table 9: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53Table 10: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55Table 11: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57Table 12: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59Table 13: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61Table 14: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62Table 15: Clinical Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 63Table 16: Genetic Testing Market, United States, Segment Contribution (%), 2011 66Table 17: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 68Table 18: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 70Table 19: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 71Table 20: Genetic Testing, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 73Table 21: Haematology Market, United States, Segment Contribution (%), 2011 76Table 22: Haematology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 78Table 23: Haematology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 80Table 24: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 82Table 25: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 84Table 26: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 86Table 27: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 88Table 28: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 90Table 29: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 92Table 30: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 94Table 31: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 96Table 32: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 98Table 33: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 100Table 34: Haematology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 101Table 35: Haematology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 103Table 36: Histology And Cytology Market, United States, Segment Contribution (%), 2011 106Table 37: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 108Table 38: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 110Table 39: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 111Table 40: Histology And Cytology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 113Table 41: Immuno Chemistry Market, United States, Segment Contribution (%), 2011 116Table 42: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 118Table 43: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 120Table 44: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 122Table 45: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 124Table 46: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 126Table 47: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 128Table 48: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 130Table 49: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 132Table 50: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 134Table 51: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 136Table 52: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 138Table 53: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 140Table 54: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 142Table 55: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 144Table 56: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 145Table 57: Immuno Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 147Table 58: Infectious Immunology Market, United States, Segment Contribution (%), 2011 149Table 59: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 151Table 60: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 153Table 61: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 155Table 62: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 157Table 63: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 158Table 64: Infectious Immunology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 160Table 65: Microbiology Culture Market, United States, Segment Contribution (%), 2011 163Table 66: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 165Table 67: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 167Table 68: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 169Table 69: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 171Table 70: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 172Table 71: Microbiology Culture, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 174Table 72: Clinical Chemisty Market Pipeline Products 191Table 73: Immuno Chemistry Market Pipeline Products 198Table 74: Haematology Market Pipeline Products 209Table 75: Infectious Immunology Market Pipeline Products 211Table 76: Microbiology Culture Market Pipeline Products 218Table 77: Histology And Cytology Market Pipeline Products 219Table 78: Genetic Testing Market Pipeline Products 220Table 79: ERBA Diagnostics Acquires Drew Scientific, Maker Of Analytical Instruments And Reagents, For $6.5 Million 225Table 80: Measurement Specialties Acquires Cambridge Technologies And Resistance Temperature Detector Company For $18.8 Million 227Table 81: Atossa Genetics Acquires Acueity Healthcare, Diagnostic Device Provider 228Table 82: AccelPath Acquires DigiPath Solutions For $2.4 Million 229Table 83: Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For $324 Million 230Table 84: Charles River Labs Acquires Accugenix, Provider Of Microbe Identification Services, For $17 Million 232Table 85: Leica Biosystems Completes Acquisition Of Aperio Technologies 233Table 86: Metabolon Acquires Lipomics Technologies, Diagnostics Company 235Table 87: Waters Acquires Blue Reference, Maker Of Application Scientific Databases, For $14 Million 237Table 88: Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 238Table 89: Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For $925 Million 239Table 90: Life Technologies Acquires Navigenics 241Table 91: Genova Diagnostics Acquires Metametrix, Clinical Laboratory 243Table 92: Luminex To Acquire GenturaDx, Molecular Diagnostics Company, For $50 Million 244Table 93: Systagenix Acquires O2 Insights 246Table 94: LabCorp Completes Acquisition Of Medtox Scientific For $241 Million 247Table 95: Flagship Biosciences Acquires Ihctech, Provider Of Research Immunohistochemistry And Histology Services 249Table 96: Halo Healthcare Acquires NeoMatrix, Maker Of Diagnostic Equipments 250Table 97: Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 251Table 98: Hologic Completes Acquisition Of Gen-Probe For $3.7 Billion 252Table 99: Haemonetics To Acquire Hemerus Medical, Provider Of Leukoreduction Technologies, For $27 Million 254Table 100: IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 255Table 101: DioGenix Enters Into Agreement With Fast Forward To Develop New Blood Test For Multiple Sclerosis 256Table 102: GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 257Table 103: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 259Table 104: CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 260Table 105: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For Colon Cancer Markers 261Table 106: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 262Table 107: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System 263Table 108: Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 264Table 109: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 265Table 110: Ezose Enters Into Co-Development Agreement With Fast Forward For Multiple Sclerosis Biomarkers 266Table 111: BioDot Enters Into Co-Marketing Agreement With JOT Automation 267Table 112: Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 268Table 113: LifeTech Scientific, DiNova Venture Partners, Themes Investment Partners And Broncus Technologies Partner To Form Broncus Medical 269Table 114: Van Andel Institute Enters Into Co-Development Agreement With Emory University 270Table 115: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 271Table 116: PGXL Labs Enters Into Joint Venture Agreement With Essential Molecular Testing 272Table 117: Broad Institute Enters Into Distribution Agreement With Appistry For Genome Analysis Toolkit 273Table 118: Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 274Table 119: Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 275Table 120: Bruker Enters Into An Agreement With Nextval For High-throughput Screening Technology 276Table 121: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 277Table 122: RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 278Table 123: Amarantus BioSciences Enters Into Option For Licensing Agreement With Memory Dx For LymPro Blood Test 279Table 124: Iverson Genetic Diagnostics Enters Into Licensing Agreement With Johns Hopkins University School For Molecular Diagnostic Tests 280Table 125: Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 281Table 126: Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 282Table 127: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx 283Table 128: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 284Table 129: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 285Table 130: Augurex Life Sciences Enters Into Licensing Agreement With Quest Diagnostics For 14-3-3n Biomarker 286Table 131: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 287Table 132: Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 288Table 133: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 290Table 134: Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 292Table 135: NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 294Table 136: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 295Table 137: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System 296Table 138: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick Detection Platform 297Table 139: CML HealthCare Enters Into Agreement With MaRS Innovation 298Table 140: Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 299Table 141: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery 300Table 142: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics 301Table 143: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 302Table 144: Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 303Table 145: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 304Table 146: ImaginAb Enters Into Co-Development Agreement With MacroGenics 305Table 147: BellBrook Labs Enters Into Co-Development Agreement With Reaction Biology 306Table 148: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 307Table 149: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 308Table 150: Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 309Table 151: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 310Table 152: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology 311Table 153: University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 312Table 154: Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 313Table 155: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 314Table 156: Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 315Table 157: Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 316Table 158: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 317Table 159: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 318Table 160: Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 319Table 161: Molecular Targeting Technologies Enters Into Licensing Agreement With Medical College of Wisconsin For 99mTc-HYNIC-Duramycin 320Table 162: Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 321Table 163: Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 322Table 164: Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 323Table 165: OriGene Technologies Enters Into Co-Development Agreement With Centre of Excellence for Prevention of Organ Failure 324Table 166: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 325Table 167: IRIS International Enters Into Distribution Agreement With Alifax 326Table 168: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 327Table 169: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 328Table 170: Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 329Table 171: RS Medical Enters Into Distribution Agreement With Harvest Technologies 330Table 172: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 331Table 173: Sandia National Labs Plans To Enter Into Licensing Agreement For SpinDx, Medical Diagnostic Tool 332Table 174: HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 333Table 175: Genisphere Enters Into Co-Development Agreement With Lankenau Institute for Medical Research 334Table 176: WaferGen Biosystems Enters Into Agreement With Integrated DNA Technologies 335Table 177: BioView Enters Into Co-Development Agreement With ScreenCell For Circulating Tumor Cell Analysis Technology 336Table 178: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 337Table 179: Fluxion Biosciences Enters Into Co-Development Agreement With Stanford University School of Medicine 338Table 180: Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 339Table 181: Phenomenome Discoveries Enters Into Licensing Agreement With Polymedco For Cancer Diagnostic Test 340Table 182: PlexPress Enters Into Technology Integration Agreement With Phalanx Biotech 341Table 183: PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 342Table 184: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays 343Table 185: Stratos Enters Into Co- Development Agreement With nanoMR 344Table 186: Guided Therapeutics Extends Licensing And Co-Development Agreement With Konica Minolta 345Table 187: Berg Pharma Enters Into Co-Development Agreement With Parkinson's Institute 346

Read the original here:
United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology ...

Comments are closed.